Trump may be kinder to healthcare mergers—to a point

President-elect Donald Trump has promised to eliminate government regulations of business, which could affect how his administration tackles issues of consolidation among health insurers and hospitals.

The New York Times reports Trump could have an immediate effect on two insurance mergers that will be contested in courts over the next few weeks. While decisions on the Anthem-Cigna and Aetna-Humana deals are likely to come before Trump takes office Jan. 20, 2017, his administration could opt for a lighter settlement deal if the insurers lose and then appeal or drop the case entirely if the U.S. Department of Justice should lose.

There’s also the possibility very little could change.

“There is a history of bipartisan support for antitrust enforcement in health care,” Leslie C. Overton, a partner at Alston & Bird and a former Justice Department official, said to the Times. “I don’t think we should expect a wholesale shift, based on the change from Democratic to Republican.”

Fighting hospital consolidation has been the job of the Federal Trade Commission, which is less likely to shift strategy no matter who is in the White House.

No matter where Trump’s priorities are, experts say the consolidation trend in healthcare will continue. Click below to find out how a repeal of the Affordable Care Act may accelerate those mergers and acquisitions. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.